ADC Therapeutics SA (ADCT) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ADCT Stock Forecast

ADC Therapeutics SA stock forecast is as follows: an average price target of $9.33 (represents a 380.93% upside from ADCT’s last price of $1.94) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.

ADCT Price Target

The average price target for ADC Therapeutics SA (ADCT) is $9.33 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $13.00 to $7.00. This represents a potential 380.93% upside from ADCT's last price of $1.94.

ADCT Analyst Ratings

Buy

According to 7 Wall Street analysts, ADC Therapeutics SA's rating consensus is 'Buy'. The analyst rating breakdown for ADCT stock is 0 'Strong Buy' (0.00%), 4 'Buy' (57.14%), 3 'Hold' (42.86%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

ADC Therapeutics SA Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
May 07, 2024	Robert Burns	H.C. Wainwright	-	-	79.78%	312.37%
Mar 13, 2024	Kelly Shi	Jefferies	-	-	233.33%	570.10%
Nov 14, 2022		Morgan Stanley	-	-	70.73%	260.82%
Sep 09, 2022	Matthew Harrison	Morgan Stanley	-	-	68.71%	467.01%
Aug 22, 2022		H.C. Wainwright	-	-	137.53%	930.93%

Row per page

Go to

The latest ADC Therapeutics SA stock forecast, released on May 07, 2024 by Robert Burns from H.C. Wainwright, set a price target of $8.00, which represents a 79.78% increase from the stock price at the time of the forecast ($4.45), and a 312.37% increase from ADCT last price ($1.94).

ADC Therapeutics SA Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	2
Avg Price Target	-	-	$10.50
Last Closing Price	$1.94	$1.94	$1.94
Upside/Downside	-100.00%	-100.00%	441.24%

In the current month, the average price target of ADC Therapeutics SA stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ADC Therapeutics SA's last price of $1.94. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
May 30, 2024	Cantor Fitzgerald		Overweight	Initialise
May 07, 2024	H.C. Wainwright	Buy	Buy	Hold
Feb 20, 2024	Needham	Buy	Buy	Hold
Aug 10, 2023	Deutsche Bank		Hold	Downgrade
Aug 10, 2023	Citigroup		Neutral	Downgrade
Nov 14, 2022	Morgan Stanley	Equal-Weight	Equal-Weight	Hold
Sep 19, 2022	H.C. Wainwright	Buy	Buy	Hold
May 10, 2022	RBC Capital	Outperform	Outperform	Hold

Row per page

Go to

ADC Therapeutics SA's last stock rating was published by Cantor Fitzgerald on May 30, 2024. The company Initialise its ADCT rating from "null" to "Overweight".

ADC Therapeutics SA Financial Forecast

ADC Therapeutics SA Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
Revenue	-	-	-	-	-	-	-	-	$16.79M	$14.49M	-	$18.99M	$69.80M	$76.32M	$17.29M	$46.50M	$17.01M	$13.15M	$3.76M	-	-	-	-
Avg Forecast	$21.20M	$20.20M	$19.20M	$18.70M	$18.73M	$18.43M	$18.89M	$18.04M	$15.31M	$15.15M	$20.25M	$20.12M	$39.38M	$60.70M	$31.22M	$37.12M	$16.47M	$7.39M	$2.23M	$94.33K	$858.00K	$42.67K	$599.00K
High Forecast	$22.19M	$21.15M	$20.10M	$19.50M	$19.00M	$18.46M	$18.89M	$18.09M	$15.60M	$15.57M	$21.20M	$21.07M	$41.23M	$60.70M	$31.22M	$37.12M	$16.47M	$7.39M	$2.23M	$94.33K	$858.00K	$42.67K	$599.00K
Low Forecast	$20.25M	$19.29M	$18.34M	$17.89M	$18.47M	$18.40M	$18.89M	$18.00M	$14.93M	$14.74M	$19.34M	$19.22M	$37.61M	$60.70M	$31.22M	$37.12M	$16.47M	$7.39M	$2.23M	$94.33K	$858.00K	$42.67K	$599.00K
# Analysts	1	1	1	2	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2
Surprise %	-	-	-	-	-	-	-	-	1.10%	0.96%	-	0.94%	1.77%	1.26%	0.55%	1.25%	1.03%	1.78%	1.69%	-	-	-	-

ADC Therapeutics SA's average Quarter revenue forecast for Mar 24 based on 2 analysts is $18.04M, with a low forecast of $18.00M, and a high forecast of $18.09M. ADCT's average Quarter revenue forecast represents a 7.47% increase compared to the company's last Quarter revenue of $16.79M (Dec 23).

ADC Therapeutics SA EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	1	1	1	2	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2
EBITDA	-	-	-	-	-	-	-	-	$-41.97M	$-34.20M	-	$-48.52M	$-10.39M	$7.44M	$-70.61M	$-23.96M	$-80.72M	$-66.47M	$-68.90M	$-49.24M	$-52.57M	$-17.76M	$-125.02M
Avg Forecast	$-10.66M	$-10.16M	$-9.66M	$-9.41M	$-9.42M	$-9.27M	$-9.50M	$-9.08M	$-7.70M	$-7.62M	$-10.18M	$-10.12M	$-19.81M	$-29.99M	$-15.43M	$-18.34M	$-8.14M	$-3.65M	$-60.09M	$-46.62K	$-424.00K	$-21.08K	$-39.04M
High Forecast	$-10.18M	$-9.70M	$-9.22M	$-9.00M	$-9.29M	$-9.26M	$-9.50M	$-9.05M	$-7.51M	$-7.41M	$-9.73M	$-9.67M	$-18.92M	$-29.99M	$-15.43M	$-18.34M	$-8.14M	$-3.65M	$-48.07M	$-46.62K	$-424.00K	$-21.08K	$-31.23M
Low Forecast	$-11.16M	$-10.64M	$-10.11M	$-9.81M	$-9.56M	$-9.29M	$-9.50M	$-9.10M	$-7.85M	$-7.83M	$-10.66M	$-10.60M	$-20.74M	$-29.99M	$-15.43M	$-18.34M	$-8.14M	$-3.65M	$-72.10M	$-46.62K	$-424.00K	$-21.08K	$-46.85M
Surprise %	-	-	-	-	-	-	-	-	5.45%	4.49%	-	4.79%	0.52%	-0.25%	4.58%	1.31%	9.92%	18.21%	1.15%	1056.20%	123.99%	842.49%	3.20%

1 analysts predict ADCT's average Quarter EBITDA for Dec 22 to be $-19.81M, with a high of $-18.92M and a low of $-20.74M. This is -366.28% lower than ADC Therapeutics SA's previous annual EBITDA (Sep 22) of $7.44M.

ADC Therapeutics SA Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	1	1	1	2	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2
Net Income	-	-	-	-	-	-	-	-	$-85.03M	$-47.81M	-	$-59.43M	$-24.16M	$-50.61M	$-64.37M	$-16.66M	$-34.38M	$-71.55M	$-72.57M	$-51.53M	$-55.93M	$-20.33M	$-126.56M
Avg Forecast	$-48.22M	$-48.22M	$-51.36M	$-50.32M	$-44.90M	$-41.41M	$-47.93M	$-58.26M	$-52.63M	$-66.46M	$-73.34M	$-2.10M	$-50.67M	$-33.77M	$-76.39M	$-64.43M	$-80.93M	$-87.76M	$-63.07M	$-86.60M	$-47.27M	$-73.68M	$-110.98M
High Forecast	$-45.40M	$-45.40M	$-48.36M	$-47.60M	$-38.10M	$-38.99M	$-45.13M	$-54.85M	$-22.37M	$-62.57M	$-69.05M	$-1.97M	$-47.70M	$-33.77M	$-76.39M	$-64.43M	$-80.93M	$-87.76M	$-50.45M	$-86.60M	$-47.27M	$-73.68M	$-88.78M
Low Forecast	$-51.16M	$-51.16M	$-54.49M	$-51.68M	$-51.70M	$-43.93M	$-50.85M	$-61.80M	$-71.05M	$-70.51M	$-77.80M	$-2.22M	$-53.75M	$-33.77M	$-76.39M	$-64.43M	$-80.93M	$-87.76M	$-75.68M	$-86.60M	$-47.27M	$-73.68M	$-133.18M
Surprise %	-	-	-	-	-	-	-	-	1.62%	0.72%	-	28.35%	0.48%	1.50%	0.84%	0.26%	0.42%	0.82%	1.15%	0.59%	1.18%	0.28%	1.14%

ADC Therapeutics SA's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ADCT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

ADC Therapeutics SA SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	1	1	1	2	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2
SG&A	-	-	-	-	-	-	-	-	$25.22M	$23.09M	-	$30.49M	$31.31M	$36.46M	$35.90M	$37.38M	$36.53M	$33.63M	$34.59M	$31.49M	$29.45M	$20.27M	$19.00M
Avg Forecast	$55.61M	$52.98M	$50.36M	$49.05M	$49.14M	$48.35M	$49.54M	$47.33M	$40.17M	$39.75M	$53.11M	$52.78M	$103.30M	$159.20M	$81.90M	$97.35M	$43.21M	$19.37M	$5.84M	$247.43K	$2.25M	$111.91K	$1.57M
High Forecast	$58.21M	$55.46M	$52.72M	$51.16M	$49.84M	$48.43M	$49.54M	$47.46M	$40.92M	$40.84M	$55.60M	$55.26M	$108.14M	$159.20M	$81.90M	$97.35M	$43.21M	$19.37M	$5.84M	$247.43K	$2.25M	$111.91K	$1.57M
Low Forecast	$53.11M	$50.60M	$48.10M	$46.92M	$48.43M	$48.27M	$49.54M	$47.20M	$39.15M	$38.65M	$50.73M	$50.41M	$98.66M	$159.20M	$81.90M	$97.35M	$43.21M	$19.37M	$5.84M	$247.43K	$2.25M	$111.91K	$1.57M
Surprise %	-	-	-	-	-	-	-	-	0.63%	0.58%	-	0.58%	0.30%	0.23%	0.44%	0.38%	0.85%	1.74%	5.93%	127.28%	13.09%	181.15%	12.09%

ADC Therapeutics SA's average Quarter SG&A projection for Mar 24 is $47.33M, based on 2 Wall Street analysts, with a range of $47.20M to $47.46M. The forecast indicates a 87.65% rise compared to ADCT last annual SG&A of $25.22M (Dec 23).

ADC Therapeutics SA EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20
# Analysts	1	1	1	2	4	2	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2
EPS	-	-	-	-	-	-	-	-	$-1.03	$-0.58	-	$-0.74	$-0.30	$-0.65	$-0.84	$-0.22	$-0.45	$-0.93	$-0.95	$-0.67	$-0.73	$-0.29	$-2.01
Avg Forecast	$-0.46	$-0.46	$-0.49	$-0.48	$-0.43	$-0.40	$-0.46	$-0.56	$-0.50	$-0.63	$-0.70	$-0.02	$-0.48	$-0.35	$-0.80	$-0.67	$-0.85	$-0.92	$-0.86	$-0.91	$-0.49	$-0.77	$-0.65
High Forecast	$-0.43	$-0.43	$-0.46	$-0.45	$-0.36	$-0.37	$-0.43	$-0.52	$-0.21	$-0.60	$-0.66	$-0.02	$-0.46	$-0.35	$-0.80	$-0.67	$-0.85	$-0.92	$-0.86	$-0.91	$-0.49	$-0.77	$-0.65
Low Forecast	$-0.49	$-0.49	$-0.52	$-0.49	$-0.49	$-0.42	$-0.49	$-0.59	$-0.68	$-0.67	$-0.74	$-0.02	$-0.51	$-0.35	$-0.80	$-0.67	$-0.85	$-0.92	$-0.86	$-0.91	$-0.49	$-0.77	$-0.65
Surprise %	-	-	-	-	-	-	-	-	2.05%	0.91%	-	37.00%	0.62%	1.84%	1.05%	0.33%	0.53%	1.01%	1.10%	0.74%	1.48%	0.38%	3.09%

According to undefined Wall Street analysts, ADC Therapeutics SA's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ADCT previous annual EPS of $NaN (undefined).

ADC Therapeutics SA Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
ALVR	AlloVir	-	-	5864.91%	Buy
ALXO	ALX Oncology	-	-	1799.22%	Buy
IPSC	Century Therapeutics	-	-	1109.68%	Buy
PASG	Passage Bio	-	-	1011.11%	Buy
BDTX	Black Diamond Therapeutics	-	-	507.00%	Buy
ADCT	ADC Therapeutics SA	-	-	380.93%	Buy
FIXX	Q32 Bio	-	-	190.32%	Buy
ARVN	Arvinas	-	-	182.76%	Buy
STOK	Stoke Therapeutics	-	-	171.52%	Buy
KURA	Kura Oncology	-	-	158.45%	Buy
RARE	Ultragenyx Pharmaceutical	-	-	132.36%	Buy
DSGN	Design Therapeutics	-	-	73.61%	Buy
AKRO	Akero Therapeutics	-	-	47.44%	Buy
RNA	Avidity Biosciences	-	-	28.05%	Buy
CRNX	Crinetics Pharmaceuticals	-	-	22.99%	Buy
PTGX	Protagonist Therapeutics	-	-	20.05%	Buy
RVMD	Revolution Medicines, Inc. Warrant	-	-	6.78%	Buy
ALEC	Alector	-	-	6.38%	Buy
AADI	Aadi Bioscience	-	-	-28.51%	Hold

ADCT Forecast FAQ

Is ADC Therapeutics SA a good buy?

Yes, according to 7 Wall Street analysts, ADC Therapeutics SA (ADCT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 57.14% of ADCT's total ratings.

What is ADCT's price target?

ADC Therapeutics SA (ADCT) average price target is $9.33 with a range of $7 to $13, implying a 380.93% from its last price of $1.94. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will ADC Therapeutics SA stock go up soon?

According to Wall Street analysts' prediction for ADCT stock, the company can go up by 380.93% (from the last price of $1.94 to the average price target of $9.33), up by 570.10% based on the highest stock price target, and up by 260.82% based on the lowest stock price target.

Can ADC Therapeutics SA stock reach $3?

ADCT's average twelve months analyst stock price target of $9.33 supports the claim that ADC Therapeutics SA can reach $3 in the near future.

What are ADC Therapeutics SA's analysts' financial forecasts?

ADC Therapeutics SA's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $74.1M (high $74.45M, low $73.75M), average EBITDA is $-37.268M (high $-37.093M, low $-37.444M), average net income is $-192M (high $-177M, low $-208M), average SG&A $194.35M (high $195.27M, low $193.44M), and average EPS is $-1.836 (high $-1.689, low $-1.987). ADCT's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $79.3M (high $82.94M, low $75.76M), average EBITDA is $-39.884M (high $-38.105M, low $-41.716M), average net income is $-198M (high $-187M, low $-208M), average SG&A $208M (high $217.55M, low $198.72M), and average EPS is $-1.89 (high $-1.782, low $-1.989).

Did the ADCT's actual financial results beat the analysts' financial forecasts?

Based on ADC Therapeutics SA's last annual report (Dec 2023), the company's revenue was $69.06M, which missed the average analysts forecast of $70.84M by -2.51%. Apple's EBITDA was $-166M, beating the average prediction of $-35.63M by 365.86%. The company's net income was $-240M, beating the average estimation of $-195M by 23.41%. Apple's SG&A was $-9.04M, missing the average forecast of $185.81M by -104.87%. Lastly, the company's EPS was $-2.94, beating the average prediction of $-1.856 by 58.43%. In terms of the last quarterly report (Dec 2023), ADC Therapeutics SA's revenue was $16.79M, beating the average analysts' forecast of $15.31M by 9.64%. The company's EBITDA was $-41.966M, beating the average prediction of $-7.702M by 444.88%. ADC Therapeutics SA's net income was $-85.031M, beating the average estimation of $-52.628M by 61.57%. The company's SG&A was $25.22M, missing the average forecast of $40.17M by -37.21%. Lastly, the company's EPS was $-1.03, beating the average prediction of $-0.502 by 105.15%